Occult HBV reactivation induced by ibrutinib treatment: a case report
de Jésus Ngoma, P.; Kabamba, Bît.; Dahlqvist, G.; Sempoux, C.; Lanthier, N.; Shindano, T.; Van Den Neste, E.; Horsmans, Y.
Acta Gastro-Enterologica Belgica 78(4): 424-426
2015
ISSN/ISBN: 1784-3227 PMID: 26712054 Document Number: 683913
Ibrutinib is a small molecule that has been recently developped for the treatment of B cell malignancies. Common side effects are diarrhoea, nausea, fatigue, infections, neutropenia and thrombocytopenia. Here we report the first case of Hepatitis B virus reactivation in a 80 years old chronic lymphocytic leukaemia patient receiving ibrutinib, suggesting that such treatment must be associated with HBV screening.